Quote:

---

While investigators initially didn't see a statistically significant death-risk reduction in the overall study group, a post hoc analysis found one group in which the benefit was clear. For patients who received low-flow oxygen, investigators recorded 70% fewer deaths for remdesivir patients compared with those on placebo. That group of patients made up 40% of the overall study.

---

Really ??? So, it helped 40% of the patients with 70% reduction on deaths and:

Quote:

---

But while remdesivir is "indeed helpful in shortening the duration of disease, reducing the progression to more complicated disease, and probably (but not definitively), saving lives," the "fine print … is perhaps less encouraging than the top line," SVB Leerink analyst Geoffrey Porges wrote in a note to clients.

The drug didn't conclusively improve survival at Day 29, "which is the endpoint of most importance in the end," he noted.

---

And then it is tried across the world in 405 hospitals in 30 countries 11,266 adults were randomized, with 2750 allocated Remdesivir and ...

Guess what ????

Quote:

---

No study drug definitely reduced mortality (in unventilated patients or any other subgroup of entry characteristics), initiation of ventilation or hospitalisation duration.

---

No benefit.

I am not telling you who do I believe .....